BridgeBio Submits NDA to FDA for BBP-418
If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may represent the first approved treatment for any form of...
Read MoreIf approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may represent the first approved treatment for any form of...
Read MoreExciting news! https://www.businesswire.com/news/home/20251215136129/en/Cure-Rare-Disease-Awarded-%247.4-Million-CIRM-Grant-to-Advance-Gene-Therapy-for-Limb-Girdle-Muscular-Dystrophy-Type-2iR9...
Read MoreExcellent news for our LGMD2I/R9 family! Link to GlobeNewswire’s article....
Read MoreThis article is featured in the October 2025 issue of Neurology(R) Clinical Practice:Limb-Girdle Muscular Dystrophy Scientific Workshop: A Multistakeholder Discussion Focused on Charting the Path Forward for Drug Development...
Read MoreCheck out our Events page for fundraising event details and how you can support this year!...
Read More